PMID- 36727776
OWN - NLM
STAT- MEDLINE
DCOM- 20231002
LR  - 20231002
IS  - 1529-4242 (Electronic)
IS  - 0032-1052 (Linking)
VI  - 152
IP  - 3
DP  - 2023 Sep 1
TI  - Role of Autologous Fat Transplantation Combined with Negative-Pressure Wound 
      Therapy in Treating Rat Diabetic Wounds.
PG  - 561-570
LID - 10.1097/PRS.0000000000010226 [doi]
AB  - BACKGROUND: Negative-pressure wound therapy (NPWT) and autologous fat 
      transplantation (AFT) are two clinical modalities for plastic and reconstructive 
      surgery. At present, there are few reports on the combination of these two 
      methods in treating diabetic wounds. This study aimed to explore the effect of 
      this combined therapy on diabetic wound healing. METHODS: Full-thickness dorsal 
      cutaneous wounds in rats with streptozotocin-induced diabetes were treated with 
      either NPWT, AFT, or combined therapy. Rats covered with commercial dressings 
      served as the control group. Macroscopic healing kinetics were examined. The 
      levels of inflammation-related factors, such as interleukin-1beta (IL-1beta), 
      interleukin-6 (IL-6), monocyte chemoattractant protein-1, arginase-1, and 
      inducible nitric oxide synthase (iNOS) and angiogenesis-related factors such as 
      vascular endothelial growth factor, were measured in the wound tissues on days 3, 
      7, and 14; immunohistochemical staining for arginase-1, iNOS, and CD31 was 
      performed on days 3, 7, and 14. The length of reepithelialization was 
      investigated on day 14. RESULTS: The combined therapy promoted faster wound 
      healing than the other treatments. The expression levels of the proinflammatory 
      factors IL-1beta, IL-6, monocyte chemoattractant protein-1 (MCP-1), and iNOS were 
      reduced, and arginase-1 expression was increased compared with those in the other 
      groups. The expression levels of vascular endothelial growth factor and CD31 in 
      the NPWT-combined-with-AFT group were significantly higher than those in the 
      other groups. Reepithelialization was faster in the NPWT-combined-with-AFT group 
      (by day 14) than in the other groups. CONCLUSION: Combining NPWT and AFT can 
      enhance diabetic wound healing by improving wound inflammation and increasing 
      wound vascularization. CLINICAL RELEVANCE STATEMENT: The authors designed a 
      randomized controlled trial of diabetic rats to confirm that NPWT can enhance the 
      vascularization and improve inflammation of the diabetic wound after the 
      autologous fat transplantation treatment. This article may provide a new idea for 
      treating diabetic wounds.
CI  - Copyright (c) 2023 by the American Society of Plastic Surgeons.
FAU - Zhang, Hao
AU  - Zhang H
AD  - From the Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of 
      Wuhan University.
FAU - Zhou, Min
AU  - Zhou M
AD  - From the Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of 
      Wuhan University.
FAU - Wang, Yu
AU  - Wang Y
AD  - From the Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of 
      Wuhan University.
FAU - Zhang, Dong
AU  - Zhang D
AD  - From the Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of 
      Wuhan University.
FAU - Qi, Baiwen
AU  - Qi B
AD  - From the Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of 
      Wuhan University.
FAU - Yu, Aixi
AU  - Yu A
AD  - From the Department of Orthopedics Trauma and Microsurgery, Zhongnan Hospital of 
      Wuhan University.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230124
PL  - United States
TA  - Plast Reconstr Surg
JT  - Plastic and reconstructive surgery
JID - 1306050
RN  - EC 3.5.3.1 (Arginase)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-6)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Animals
MH  - Rats
MH  - Arginase
MH  - Chemokine CCL2
MH  - *Diabetes Mellitus, Experimental/complications/therapy
MH  - Inflammation
MH  - Interleukin-6
MH  - *Negative-Pressure Wound Therapy
MH  - Vascular Endothelial Growth Factor A
EDAT- 2023/02/03 06:00
MHDA- 2023/09/01 06:43
CRDT- 2023/02/02 07:45
PHST- 2023/09/01 06:43 [medline]
PHST- 2023/02/03 06:00 [pubmed]
PHST- 2023/02/02 07:45 [entrez]
AID - 00006534-990000000-01519 [pii]
AID - 10.1097/PRS.0000000000010226 [doi]
PST - ppublish
SO  - Plast Reconstr Surg. 2023 Sep 1;152(3):561-570. doi: 
      10.1097/PRS.0000000000010226. Epub 2023 Jan 24.